Neuroendocrinology · 2008 · 57 citations · 42 references
MedicineEndocrinologyOncologyEndocrine OncologyGastrointestinal OncologyMolecular OncologyCancer BiomarkersEndocrine Tumor DiagnosisEndocrine Tumor PathologyEndocrine Tumor PrognosisEndocrine TumorsMalignant NeoplasmsClinical Survival RatesClinicopathological CorrelationMolecular Prognostic MarkersPrognostic ClassificationSomatostatin Analog TherapySomatostatin AnaloguesSomatostatin Receptor ExpressionSurvival Rates
The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somatostatin receptors (SSTR). To correlate the expression of SSTR subtypes by reverse transcriptase-polymerase chain reaction (RT-PCR) with clinicopathological features and survival in a group of WDEC patients, 42 WDEC tissue specimens from 33 patients were analysed. All patients were treated with somatostatin analogues and had a median follow-up period of 45 months (range 6-196). Neither SSTR2 and SSTR5 expression nor Ki-67 level alone correlated with survival. A significantly better survival rate was observed in patients with tumours expressing SSTR2, SSTR5 and Ki-67 <2%, compared to those with SSTR2- and SSTR5-negative tumours and Ki-67 >or=2% (p < 0.038), with 5-year survival rates of 91 vs. 43%, respectively. Expression of SSTR2 and SSTR5 appears to play a positive prognostic role, possibly correlated with the high affinity that the available somatostatin analogues display for these 2 specific SSTR subtypes.
42
Executive functions in children with Autism Spectrum Disorders
Sally Robinson, Lorna Goddard, Barbara Dritschel et al. · Brain and Cognition · 2009 · 405 citations